Moffitt Cancer Center Logo
 

Mohamed A. Kharfan-Dabaja, MD

Where You Are:
Mohamed A. Kharfan-Dabaja, MD

Senior Member

"Dr. Kharfan-Dabaja is developing trials in reduced intensity conditioning stem cell transplants for chronic lymphocytic leukemias and low grade lymphomas."

Office  (813) 745-8530

Education And Training
  • Fellow, University of Miami- Jackson Memorial Hospital, 2002 - Medical Oncology- Hematology
  • Resident, Good Samaritan Hospital of Maryland, 1999 - Internal Medicine
  • Intern, Good Samaritan Hospital of Maryland, 1997
  • MD, American University of Beirut School of Medicine, 1995
  • BSc, American University of Beirut, 1991


- Chronic lymphocytic leukemias

- non-myeloablative stem cell tranplantation conditioning regimens

  • Kharfan-Dabaja MA, Wierda WG, Cooper LJ. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia. 2014 Mar;28(3):507-517. Pubmedid: 24157582.
  • McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ. Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biol Blood Marrow Transplant. 2014 Mar. Pubmedid: 24641829.
  • Zeidan AM, Kharfan-Dabaja MA, Komrokji RS. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Curr Opin Hematol. 2014 Mar;21(2):123-130. Pubmedid: 24335709.
  • Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2014 Feb. Pubmedid: 24534108.
  • Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplant. 2014 Jan;49(1):11-16. Pubmedid: 23995098.
  • Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA. Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. Semin Hematol. 2014 Jan;51(1):73-86. Pubmedid: 24468319.
  • Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN. Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. Bone Marrow Transplant. 2014 Jan. Pubmedid: 24442246.
  • Nishihori T, Hassoun Y, Zhang L, Shain K, Alsina M, Kharfan-Dabaja MA. High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation. Bone Marrow Transplant. 2014 Jan;49(1):148-149. Pubmedid: 23933759.
  • Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013 Nov;163(3):315-325. Pubmedid: 24033280.
  • Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?. Bone Marrow Transplant. 2013 Nov;48(12):1489-1496. Pubmedid: 23584438.
  • Otrock ZK, Saab J, Aftimos G, Nasr F, Farhat FS, Khairallah S, Abadjian G, Ghosn M, Sidani H, Ibrahim A, Tawil A, Ghorra C, Meguerian Z, Mokaddem W, Dayeh W, Salem Z, Chahine G, Bitar N, Mugharbel A, Makdessi J, Khater C, El Hajj M, Abi Gerges D, Sfeir C, Kattan J, Ibrahim K, Saade M, Sadek H, Mahfouz RA, Kharfan-Dabaja MA, Zaatari G, Bazarbachi A. A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses. Pathol Oncol Res. 2013 Oct;19(4):715-722. Pubmedid: 23653112.
  • Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA. Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy. 2013 Sep;5(9):1005-1020. Pubmedid: 23998734.
  • Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol. 2013 Jul;6:2. Pubmedid: 23289975. Pmcid: PMC3548722.
  • Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 2013 Jul;122(4):499-506. Pubmedid: 23692856. Pmcid: PMC3724189.
  • Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II Study of CD4(+)-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting. Biol Blood Marrow Transplant. 2013 May;19(7):1087-1093. Pubmedid: 23632090.
  • El-Jurdi N, Reljic T, Kumar A, Pidala J, Bazarbachi A, Djulbegovic B, Kharfan-Dabaja MA. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy. 2013 May;5(5):457-466. Pubmedid: 23638742.
  • El-Majzoub N, Kharfan-Dabaja MA, Boulos FI, Mahfouz R, Eloubeidi MA. Diagnosing diffuse large B-cell non-hodgkin lymphoma by endoscopic ultrasound-fine-needle aspiration of a splenic mass. J Clin Oncol. 2013 May;31(13):e223-e225. Pubmedid: 23530099.
  • Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Apr. Pubmedid: 23605934.
  • Kharfan-Dabaja MA, Nishihori T, Otrock ZK, Haidar N, Mohty M, Hamadani M. Monoclonal Antibodies in Conditioning Regimens for Hematopoietic Cell Transplantation. Biol Blood Marrow Tran. 2013 Apr;19(9):1288-1300. Pubmedid: 23618718.
  • Nishihori T, Abu Kar SM, Baz R, Alsina M, Harousseau JL, Kharfan-Dabaja MA. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013 Feb;19(8):1144-1151. Pubmedid: 23416092.
  • Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2013 Feb;19(7):1006-1012. Pubmedid: 23396213.
  • Bazarbachi A, Labopin M, Ghavamzadeh A, Giebel S, Al-Zahrani H, Ladeb S, Leone G, Abdel-Rahman F, Liso V, Hamidieh AA, Rasheed W, Ibrahim A, Alabdulaaly A, Kyrcz-Krzemien S, Arnold R, Kharfan-Dabaja MA, Alimoghaddam K, Aljurf M, Mohty M. Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers. Bone Marrow Transplant. 2013 Jan;48(8):1065-1069. Pubmedid: 23353802.
  • Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Smith LR, Rolland AP, Kenney RT. Reanalysis of TransVax immunogenicity. Lancet Infect Dis. 2013 Jan;13(1):18. Pubmedid: 23257230.
  • Baydoun M, Otrock ZK, Okaily S, Nehme R, Abu-Chahine R, Hamdan A, Noureddine S, Kanj S, Kanafani Z, Bazarbachi A, Kharfan-Dabaja MA. Prophylactic administration of doxycycline reduces central venous catheter infections in patients undergoing hematopoietic cell transplantation. Mediterr J Hematol Infect Dis. 2013;5(1):e2013015. Pubmedid: 23505603. Pmcid: PMC3591294.
  • Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012 Dec;97(12):1882-1889. Pubmedid: 22689677.
  • Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov;87(11):1006-1009. Pubmedid: 23090887.
  • Zibara K, Hamdan R, Dib L, Sindet-Pedersen S, Kharfan-Dabaja M, Bazarbachi A, El-Sabban M. Acellular bone marrow extracts significantly enhance engraftment levels of human hematopoietic stem cells in mouse xeno-transplantation models. PLoS One. 2012 Nov;7(7):e40140. Pubmedid: 22768336. Pmcid: PMC3388059.
  • Kharfan-Dabaja MA, Otrock ZK, Bacigalupo A, Mahfouz RA, Geara F, Bazarbachi A. A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita. Bone Marrow Transplant. 2012 Sep;47(9):1254-1255. Pubmedid: 22246089.
  • Kharfan-Dabaja MA, Pidala J, Kumar A, Terasawa T, Djulbegovic B. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplant. 2012 Sep;47(9):1164-1170. Pubmedid: 22562081.
  • Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tran. 2012 Jul;18(7):1099-1107. Pubmedid: 22198540.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Br J Haematol. 2012 Jun;157(5):553-563. Pubmedid: 22449149.
  • Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May;118(10):2659-2664. Pubmedid: 21956402.
  • Kumar A, Mhaskar AR, Reljic T, Mhaskar RS, Kharfan-Dabaja MA, Anasetti C, Mohty M, Djulbegovic B. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012 Apr;26(4):582-588. Pubmedid: 22182922.
  • Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012 Apr;12(4):290-299. Pubmedid: 22237175.
  • Sibai H, Ishak RS, Halawi R, Otrock ZK, Salman S, Abu-Alfa A, Kharfan-Dabaja MA. Non-uremic calcific arteriolopathy (calciphylaxis) in relapsed/refractory Hodgkin's lymphoma: a previously unreported association. J Clin Oncol. 2012 Mar;30(7):e88-e90. Pubmedid: 22231039.
  • Kharfan-Dabaja MA, Bazarbachi A. Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens. Cancer Control. 2012 Jan;19(1):68-75. Pubmedid: 22143063.
  • Kanate AS, Kharfan-Dabaja MA, Hamadani M. Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma. Bone Marrow Res. 2012;2012:897215. Pubmedid: 23097707. Pmcid: PMC3477524.
  • Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-511. Pubmedid: 21813352.
  • Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec;35(12):1571-1577. Pubmedid: 21752466.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Ayala E, Perez L, Fernandez H, Fancher K, Tate C, Shaw LM, Milone MC, Gardiner JA, Miller S, Anasetti C. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone Marrow Transplant. 2011 Nov;46(11):1418-1425. Pubmedid: 21132026.
  • Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev. 2011 Nov;(10):CD008818. Pubmedid: 21975786.
  • Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, Janssen W, Kharfan-Dabaja MA, Ochoa L, Perez L, Perkins J, Raychaudhuri J, Fernandez H, Anasetti C. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Tran. 2011 Oct;17(10):1505-1511. Pubmedid: 21385623.
  • Ang C, O'Reilly EM, Abou-Alfa GK, Shamseddine A, Skouri H, Tawil A, Eloubeidi MA, Lowery M, Kharfan-Dabaja M, Kaprealian T, Temraz S, Sibai H, Farran H, Shah MA. Gastrointestinal cancer educational case series: management of metastatic adenocarcinoma of unknown primary origin in a Ph+ ALL survivor. J Gastrointest Cancer. 2011 Sep;42(3):165-170. Pubmedid: 21128012.
  • Nishihori T, Fernandez HF, Coppola D, Ochoa-Bayona JL, Lancet JE, Komrokji RS, Kharfan-Dabaja MA. Hepatobiliary manifestations of acute myeloid leukemia. Leuk Res. 2011 Jun;35(6):e81-e83. Pubmedid: 21232795.
  • Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):257-260. Pubmedid: 21658652.
  • Kharfan-Dabaja MA, Cutler CS. Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol. 2011 May;93(5):578-585. Pubmedid: 21547615.
  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, Perkins J, Ayala E, Perez L, Fernandez H. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transplant. 2011 May;46(5):641-649. Pubmedid: 20711242.
  • Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancetf J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Tran. 2011 Mar;17(3):384-393. Pubmedid: 20655389.
  • Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011 Mar;35(3):301-304. Pubmedid: 21109304.
  • Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol. 2011 Feb;93(2):206-212. Pubmedid: 21246311.
  • Pidala J, Kim J, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez H, Anasetti C. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. Biol Blood Marrow Tran. 2011 Feb;17(2):239-248. Pubmedid: 20637884.
  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol. 2011 Jan;3:36. Pubmedid: 20925957. Pmcid: PMC2958877.
  • Nishihori T, Kharfan-Dabaja MA, Ochoa-Bayona JL, Bazarbachi A, Pasquini M, Alsina M. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. Hematol Oncol Stem Cell Ther. 2011;4(1):1-9. Pubmedid: 21460601.
  • Nishihori T, Perkins J, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. Am J Hematol. 2010 Nov;85(11):904-907. Pubmedid: 20890908.
  • Kharfan-Dabaja MA, Bazarbachi A. Emerging Role of CD20 Blockade in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2010 Oct;16(10):1347-1354. Pubmedid: 20083213.
  • Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010 Aug;45(8):1347-1351. Pubmedid: 19966849.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Tran. 2010 Jul;16(7):937-947. Pubmedid: 20102746.
  • Kharfan-Dabaja MA, Pidala J, Anasetti C. Thrombotic microangiopathy after GVHD prophylaxis with tacrolimus/sirolimus: a call for use of consensus definition in reporting. Blood. 2010 May;115(21):4316-4317. Pubmedid: 20508174.
  • Pidala J, Kim J, Perkins J, Field T, Fernandez H, Perez L, Ayala E, Kharfan-Dabaja M, Anasetti C. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant. 2010 May;45(5):919-924. Pubmedid: 19767783.
  • Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell MJ, Huang Y, Anasetti C, Perkins J. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant. 2010 Apr;45(4):662-667. Pubmedid: 19684623. Pmcid: PMC2850960.
  • Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010 Feb;45(2):255-260. Pubmedid: 19543327.
  • Kharfan-Dabaja MA, Velez A, Richards K, Greene JN, Field T, Sandin R. Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. Int J Hematol. 2010 Jan;91(1):124-127. Pubmedid: 20013322.
  • Mourad AR, Kharfan-Dabaja MA, Benson K, Moscinski LC, Baz RC. Leptomeningeal myeloma as the sole manifestation of relapse: an unusual presentation. Am J Med Sci. 2010 Jan;339(1):81-82. Pubmedid: 19875952.
  • Pidala J, Anasetti C, Kharfan-Dabaja MA, Cutler C, Sheldon A, Djulbegovic B. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009 Nov;15(11):1415-1421. Pubmedid: 19822301.
  • Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, Fernandez H, Perez L, Ayala E, Anasetti C. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Sep;15(9):1116-1121. Pubmedid: 19660725.
  • Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2009 Sep;15(9):1005-1013. Pubmedid: 19660713.
  • Mhaskar R, Kumar A, Behera M, Kharfan-Dabaja MA, Djulbegovic B. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant. 2009 Aug;15(8):893-902. Pubmedid: 19589478.
  • Matos-Fernandez NA, Abou Mourad YR, Caceres W, Kharfan-Dabaja MA. Current status of allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Tran. 2009 Jun;15(6):656-661. Pubmedid: 19450749.
  • Fernandez HF, Kharfan-Dabaja MA. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities. Cancer Control. 2009 Apr;16(2):153-157. Pubmedid: 19337201.
  • Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009 Jan;101(2):100-106. Pubmedid: 19141779.
  • Kharfan-Dabaja M, Chavez J, Khorfan K, Pinilla-Ibarz J. Clinical and therapeutic implications of the mutational status of IgVH inpatients with chronic lymphocytic leukemia. Cancer. 2008 Sep;113(5):897-906. Pubmedid: 18618518.
  • Abou Mourad YR, Fernandez HF, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Biol Blood Marrow Tran. 2008 Sep;14(9):949-958. Pubmedid: 18721758.
  • Raychaudhuri J, Cualing H, Haider K, Kharfan-Dabaja M. Granulocytic sarcoma and chronic lymphocytic leukemia of the gastrointestinaltract after allogeneic hematopoietic cell transplantation mimickinggraft-versus-host disease. Leuk Lymphoma. 2008 Feb;49(2):350-352. Pubmedid: 18231925.
  • Kharfan-Dabaja M, Fahed R, Hussein M, Santos E. Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2007 Nov;16(11):1799-1815. Pubmedid: 17970639.
  • Kharfan-Dabaja M, Kumar A, Behera M, Djulbegovic B. Systematic review of high dose chemotherapy and autologous haematopoietic stemcell transplantation for chronic lymphocytic leukaemia: what is the publishedevidence. Br J Haematol. 2007 Oct;139(2):234-242. Pubmedid: 17897299.
  • Kharfan-Dabaja M, Abou Mourad Y, Fernandez H, Pasquini M, Santos E. Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. Biol Blood Marrow Transplant. 2007 Sep;13(9):997-1004. Pubmedid: 17697961.
  • Kharfan-Dabaja M, Anasetti C, Santos E. Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. Biol Blood Marrow Transplant. 2007 Apr;13(4):373-385. Pubmedid: 17382245.
  • Kharfan-Dabaja MA, Anasetti C, Ferrara JL. Sympathectomy protects denervated skin from graft-versus-host disease. Biol Blood Marrow Transplant. 2007 Mar;13(3):369-370. Pubmedid: 17317591.
  • Kharfan-Dabaja MA, Ayala E, Greene J, Rojiani A, Murtagh F, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007 Feb;39(4):253-254. Pubmedid: 17290282.
  • Kharfan-Dabaja M, Ayala E, Greene J, Rojiani A, Murtagh F, Anasetti C. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007 Jan;39(2): 101-7. Pubmedid: 17143300.
  • Santos E, Kharfan-Dabaja M, Ayala E, Raez L. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Dec;47(12):2453-2476. Pubmedid: 17169792.
  • Santos E, Kharfan-Dabaja M. New horizons in multiple myeloma therapy. Expert Rev Anticancer Ther. 2006 Oct;6(10):1483-1501. Pubmedid: 17069532.
  • Kharfan-Dabaja M, Patel S, Osunkoya A, Kojouri K, Kamble R, Yang J, HashmiM, Ozer H, Selby G. Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining. Clin Lab Haematol. 2006 Aug;28(4):254-258. Pubmedid: 16898965.
  • Kamble R, Selby G, Mims M, Kharfan-Dabaja M, Ozer H, George J. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Tr. 2006 May;12(5):506-510. Pubmedid: 16635785.
  • Dunn T, Allen R, Bates F, Kurkjian C, Kamble R, Kharfan-Dabaja M. Cytogenetic changes associated with myelodysplastic syndrome affecting bone marrow engraftment analysis. J Mol Diagn. 2006 May;8(2):288-294. Pubmedid: 16645218. Pmcid: PMC1867594.
  • Hamadani M, Kharfan-Dabaja M, Kamble R, Kern W, Ozer H. Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature. J Okla State Med Assoc. 2006 Apr;99(4):154-156. Pubmedid: 16703935.
  • Kurkjian C, Patel S, Kamble R, Dunn S, Kern W, Kharfan-Dabaja M. Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet. 2006 Mar;165(2):176-179. Pubmedid: 16527614.
  • Ayala E, Kharfan-Dabaja M. Protective conditioning for acute graft-versus-host disease. New England J Med. 2005 Dec;353(25):2718-2718. Pubmedid: 16371641.
  • Kamble R, Pant S, Selby G, Kharfan-Dabaja M, Sethi S, Kratochvil K, KohrtN, Ozer H. Microbial contamination of hematopoietic progenitor cell grafts-incidence, clinical outcome, and cost-effectiveness: an analysis of 735 grafts. Transfusion. 2005 Jun;45(6):874-878. Pubmedid: 15934984.
  • Kurkjian C, Armor JF, Kamble R, Ozer H, Kharfan-Dabaja MA. Symptomatic metastases to the pituitary infundibulum resulting from primary breast cancer. Int J Clin Oncol. 2005 Jun;10(3):191-194. Pubmedid: 15990968.
  • Armor J, Fazili J, Toubia N, Kern W, Kamble R, Kharfan-Dabaja M. Remission of natural-killer cell lymphoma of the liver with anti-hepatitis C therapy. Am J Hematol. 2005 Mar;78(3):212-215. Pubmedid: 15726605.
  • Li Q, Ozer H, Lindner I, Lee K, Kharfan-Dabaja M. Protein kinase C blockade inhibits differentiation of myeloid blasts into dendritic cells by calcium ionophore A23187. Int J Hematol. 2005 Feb;81(2):131-137. Pubmedid: 15765781.
  • Kharfan-Dabaja M, Ayala E, Lindner I, Cejas P, Bahlis N, Kolonias D, CarlsonLM, Lee K. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol Immunother. 2005 Jan;54(1):25-36. Pubmedid: 15693136.
  • Ayala E, Rosado MF, Morgensztern D, Kharfan-Dabaja MA, Byrnes JJ. Heparin-induced thrombocytopenia presenting with thrombosis of multiple saphenous vein grafts and myocardial infarction. Am J Hematol. 2004 Aug;76(4):383-385. Pubmedid: 15282674.
  • Khan M, Hussein K, Walter M, Hasan M, Kern W, Kharfan-Dabaja M. Granulocytic sarcoma presenting with malignant anasarca in a patient with secondary acute myeloid leukemia. Int J Hematol. 2004;79(3):250-252. Pubmedid: 15168593.
  • Lindner I, Kharfan-Dabaja MA, Ayala E, Kolonias D, Carlson LM, Beazer-Barclay Y, Scherf U, Hnatyszyn JH, Lee KP. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL. J Immunol. 2003 Aug;171(4):1780-1791. Pubmedid: 12902478.
  • Santos ES, Raez LE, Kharfan-Dabaja MA, Angulo J, Restrepo A, Byrnes JJ. Survival of renal allograft following de novo hemolytic uremic syndrome after kidney transplantation. Transplant P. 2003 Jun;35(4):1370-1374. Pubmedid: 12826162.
  • Kharfan-Dabaja M, Morgensztern D, Santos E, Goodman M, Fernandez H. Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant. Bone Marrow Transplant. 2003 Jan;31(2):129-131. Pubmedid: 12621495.
  • Bahlis N, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez H, Boise L, Lee K. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res. 2002 Dec;8(12):3658-3668. Pubmedid: 12473574.
  • Couriel DR, Beguelin GZ, Giralt S, De Lima M, Hosing C, Kharfan-Dabaja MA, Anagnostopoulos A, Champlin R. Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation. Bone Marrow Transplant. 2002 Oct;30(8):543-546. Pubmedid: 12379897.
  • Morgensztern D, Kharfan-Dabaja M, Tsai H, Lian E. Warm-antibody autoimmune hemolytic anemia developing after thrombotic thrombocytopenic purpura. Acta Haematol. 2002;108(3):154-156. Pubmedid: 12373088.
  • Kharfan Dabaja MA, Morgensztern D, Markoe AM, Bartlett-Pandite L. Radiation recall dermatitis induced by methotrexate in a patient with Hodgkin's disease. Am J Clin Oncol. 2000 Oct;23(5):531-533. Pubmedid: 11039518.
  • Pidala J, Kim J, Roman-Diaz J, Shapiro J, Nishihori T, Bookout R, Anasetti C, Kharfan-Dabaja MA. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Ann Transplant. 15(4):21-29. Pubmedid: 21183872.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer